Factors inducing mast cell accumulation in skeletal muscle

Neuropathology and Applied Neurobiology

Volumn 22, Issue 3, 1996, Pages 248-255

  Lefaucheur, J P ^a   Gjata, B ^a   Sebille, A ^a  

^a SORBONNE UNIVERSITÉ   (France)

Author keywords

Denervation devascularization; Dystrophin; Mast cell; mdx mice; Muscle regeneration; Notexin; Phospholipase A2; Skeletal muscle

Indexed keywords

DYSTROPHIN; NOTEXIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CONTROLLED STUDY; MAST CELL; MOUSE; MUSCLE NECROSIS; MUSCLE REGENERATION; NONHUMAN; PRIORITY JOURNAL; SKELETAL MUSCLE;

EID: 0029936092     PISSN: 03051846     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2990.1996.tb00901.x     Document Type: Article

References (45)

1. Allen RE, Dodson MV, Luiten LS. Regulation of skeletal muscle satellite cell proliferation by bovine pituitary fibroblast growth factor. Exp Cell Res 1984; 152: 154-60
2. Bashkin P, Doctrow S, Klagsbrun M, Svahn CM, Folkman J, Vlodavsky I. Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules. Biochemistry 1989; 28: 1737-43
3. Beam KG. Duchenne muscular dystrophy, localising the gene product. Nature 1988; 333: 798-9
4. Bergstresser PR, Tigelaar RK, Tharp MD. Conjugated avidin identifies cutaneous rodent and human mast cells. J Invest Dermatol 1984; 83: 214-8
5. Bodensteiner JB, Engel AG. Intracellular calcium accumulation in Duchenne dystrophy and other myopathies: a study of 567,000 muscle libres in 114 biopsies. Neurology 1978; 28: 439-46
6. Boxler K, Jerusalem F. Hyperreactive (hyaline, opaque, dark) muscle fibers in Duchenne dystrophy. A biopsy study of 16 dystrophy and 205 other neuromuscular disease cases and controls. J Neurol 1978; 219: 63-72
7. Bussolati G, Gugliotta P. Nonspecific staining of mast cells by avidin-biotin-peroxidase complexes (ABC). J Histochem Cytochem 1983; 31: 1419-21
8. Chang J, Musser JH, McGregor H. Phospholipase A2: function and pharmacological regulation. Biochem Pharmacol 1987; 36: 2429-36
9. Florini JR, Roberts AB, Ewton DZ, Falen SB, Flanders KC, Sporn MB. Transforming Growth Factor β. A very potent inhibitor of myoblast differentiation, identical to the differentiation inhibitor secreted by buffalo rat liver cells. J Biol Chem 1986; 261: 16509-13
10. Folkman J, Klagsbrun M, Sasse J, Wadzinski M, Ingber D, Vlodavsky I. A heparin-binding angiogenic protein, basic fibroblast growth factor, is stored within basement membrane. Am J Pathol 1988; 130: 393-400
11. Galli SJ. New insights into 'the riddle of the mast cells': microenvironmental regulation of mast cell development and phenotypic heterogeneity. Lab Invest 1990; 62: 5-33
12. Galli SJ. New concepts about the mast cell. N Engl J Med 1993; 328: 257-65
13. Galli SJ, Gordon JR, Wershil BK. Cytokine production by mast cells and basophils. Curr Opin Immunol 1991; 3: 865-73
14. Gorospe JRM, Tharp M, Demitsu T, Hodman EP. Dystrophin-deficient myofibers are vulnerable to mast cell granule-induced necrosis. Neuromusc Disord 1994; 4: 325-33
15. Gorospe JRM, Tharp M, Hinckley J, Kornegay JN, Hoffman EP. A role for mast cells in the progression of Duchenne muscular dystrophy? Correlations in dystrophin-deficient humans, dogs, and mice. J Neurol Sci 1994; 122: 44-56
16. Gospodarowicz D, Cheng J. Heparin protects basic and acidic FGF from inactivation. J Cell Physiol 1986; 128: 475-84
17. Gospodarowicz D, Weseman J, Moran JS, Lindstrom J. Effect of fibroblast growth factor on the division and fusion of bovine myoblasts. J Cell Biol 1976; 70: 395-405
18. Harris JB, Cullen MJ. Muscle necrosis caused by snake venoms and toxins. Electron Microsc Rev 1990; 3: 183-211
19. Harris JB, MacDonell CA. Phospholipase A2 activity of notexin and its role in muscle damage. Toxicon 1981; 19: 419-30
20. Hawkins RA, Claman HN, Clark RAF, Steigerwald JC. Increased dermal mast cell populations in progressive systemic sclerosis: a link in chronic fibrosis? Ann Intern Med 1985; 102: 182-6
21. Helliwell TR, Gunhan O, Edwards RHT. Mast cells in neuromuscular diseases. J Neurol Sci 1990; 98: 267-76
22. Karpati G, Carpenter S, Melmed C, Eisen AA. Experimental ischemic myopathy. J Neurol Sci 1974; 23: 129-61
23. Kitamura Y. Heterogeneity of mast cells and phenotypic change between subpopulations. Annu Rev Immunol 1989; 7: 59-76
24. Lefaucheur JP, Pastoret C, Sebille A. Phenotype of dystrophinopathy in old mdx mice. Anat Rec 1995; 242: 70-6
25. Lefaucheur JP, Sebille A. The basic fibroblast growth factor-saporin mitotoxin impairs in vivo skeletal muscle regeneration following injury. Neuromusc Disord 1993; 3: 367-70
26. Lefaucheur JP, Sebille A. Muscle regeneration following injury can be modified in vivo by immune neutralization of bFGF, TGFβ1 or IGF-I. J Neuroimmunol 1995; 57: 85-91
27. Lefaucheur JP, Sebille A. The cellular events of injured muscle regeneration depend on the nature of the injury. Neuromusc Disord 1995; 5: 501-9
28. Lindahl M, Bäckman E, Henriksson KG, Gorospe JR, Hollman EP. Phospholipase A2 activity in dystrophinopathies. Neuromusc Disord 1995; 5: 193-9
29. Massagué J, Cheifetz S, Endo T, Nadal-Ginard B. Type β Transforming Growth Factor is an inhibitor of myogenic differentiation. Proc Natl Acad Sci USA 1986; 83: 8206-10
30. Menke A, Jockusch H. Decreased osmotic stability of dystrophin-less muscle cells from the mdx mouse. Nature 1991; 349: 69-71
31. Nonaka I, Takagi A, Ishiura S, Nakase H, Sugita H. Pathophysiology of muscle fiber necrosis induced by bupivacaine hydrochloride (Marcaine). Acta Neuropathol 1983; 60: 167-74
32. Ovalle WK, Dow PR. Distribution of mast cells and their relationship to muscle spindles in normal and genetically dystrophic skeletal muscles. Anat Rec 1982; 202: 142 A
33. Pastoret C, Sebille A. Mdx mice show progressive weakness and muscle deterioration with age. J Neurol Sci 1995; 129: 97-105
34. Petrof BJ, Shrager JB, Stedman HH, Kelly AM, Sweeney HL. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci USA 1993; 90: 3710-4
35. Presta M, Maier JAM, Rusnati M, Ragnotti G. Basic fibroblast growth factor is released from endothelial extracellular matrix in a biologically active form. J Cell Physio 1989; 140: 68-74
36. Pruzanski W, Vadas P. Phospholipase A2: a mediator between proximal and distal effectors of inflammation. Immunol Today 1991; 12: 143-6
37. Rusnati M, Urbinati C, Presta M. Internalization of basic fibroblast growth factor (bFGF) in cultured endothelial cells: role of the low affinity heparin-like bFGF receptors. J Cell Physiol 1993; 154: 152-61
38. Sainte-Marie G, Peng FS. Mast cells and fibrosis in compartments of lymph nodes of normal, gnotobiotic, and athymic rats. Cell Tissue Res 1990; 261: 1-15
39. Saksela O, Moscatelli D, Sommer A, Rifkin DB. Endothelial cell derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation. J Cell Biol 1988; 17: 743-51
40. Taipale J, Lohi J, Saarinen J, Kovanen PT, Keski-Oja J. Human mast cell chymase and leukocyte elastase release latent transforming growth factor-β1 from the extracellular matrix of cultured human epithelial and endothelial cells. J Biol Chem 1995; 270: 4689-96
41. Tharp MD, Seelig LL, Tigelaar RE, Bergstresser PR. Conjugated avidin binds to mast cell granules. J Histochem Cytochem 1985; 33: 27-32
42. Tsai M, Gordon JR, Galli SJ. Mast cells constitutively express transforming growth factor β m RNA. FASEB J 1990; 4: A1944
43. Turner PR, Fong P, Denetclaw WF, Steinhardt RA. Increased calcium influx in dystrophic muscle. J Cell Biol 1991; 115: 1701-12
44. Turner PR, Westwood T, Regen CM, Steinhardt RA. Increased protein degradation results from elevated free calcium levels found in muscle from mdx mice. Nature 1988; 335: 735-8
45. Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz DM. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 1991; 64: 841-8